Interfax informs about it with reference to the press service of the center.
It is noted that at first it is planned to conduct a separate post-marketing clinical trial of the vaccine with the participation of 150 volunteers over 60 years old.
“Further, large-scale placebo-controlled studies will be conducted, which will begin in the Siberian region for 5 thousand volunteers aged 18 to 60 years and will continue in the regions,” Vektor said.
Earlier, the head of Rospotrebnadzor Anna Popova said that clinical trials of the coronavirus vaccine developed by the Vector Center have been completed.